SI2465580T1 - Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo - Google Patents
Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazoInfo
- Publication number
- SI2465580T1 SI2465580T1 SI200631747T SI200631747T SI2465580T1 SI 2465580 T1 SI2465580 T1 SI 2465580T1 SI 200631747 T SI200631747 T SI 200631747T SI 200631747 T SI200631747 T SI 200631747T SI 2465580 T1 SI2465580 T1 SI 2465580T1
- Authority
- SI
- Slovenia
- Prior art keywords
- inhibitory activity
- hiv integrase
- integrase inhibitory
- polycyclic carbamoylpyridone
- carbamoylpyridone derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005131161 | 2005-04-28 | ||
JP2005312076 | 2005-10-27 | ||
EP12159082.2A EP2465580B1 (en) | 2005-04-28 | 2006-04-28 | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2465580T1 true SI2465580T1 (sl) | 2014-04-30 |
Family
ID=37215098
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632268T SI3045206T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
SI200632344T SI3284520T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
SI200632418T SI3187225T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze |
SI200632410T SI3372281T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze |
SI200631703T SI1874117T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
SI200631747T SI2465580T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200632268T SI3045206T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
SI200632344T SI3284520T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
SI200632418T SI3187225T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo HIV integraze |
SI200632410T SI3372281T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivati, ki imajo aktivnost inhibitorja HIV integraze |
SI200631703T SI1874117T1 (sl) | 2005-04-28 | 2006-04-28 | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
Country Status (29)
Country | Link |
---|---|
US (21) | US8129385B2 (sl) |
EP (9) | EP3187226A1 (sl) |
JP (2) | JP4295353B2 (sl) |
KR (4) | KR101363875B1 (sl) |
AU (1) | AU2006239177B8 (sl) |
BR (1) | BRPI0610030B8 (sl) |
CA (1) | CA2606282C (sl) |
CY (6) | CY1115151T1 (sl) |
DK (6) | DK3284520T3 (sl) |
EA (1) | EA014162B1 (sl) |
ES (7) | ES2667868T5 (sl) |
FI (1) | FIC20210017I1 (sl) |
FR (1) | FR14C0041I2 (sl) |
HK (4) | HK1107227A1 (sl) |
HU (6) | HUE037795T2 (sl) |
IL (4) | IL186555A (sl) |
LT (4) | LT3372281T (sl) |
LU (2) | LU92446I2 (sl) |
MA (1) | MA29460B1 (sl) |
MX (2) | MX302718B (sl) |
NL (2) | NL300676I2 (sl) |
NO (5) | NO339525B1 (sl) |
NZ (1) | NZ562339A (sl) |
PL (5) | PL3372281T3 (sl) |
PT (5) | PT3372281T (sl) |
SI (6) | SI3045206T1 (sl) |
TW (1) | TWI378931B (sl) |
VN (1) | VN34404A1 (sl) |
WO (1) | WO2006116764A1 (sl) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2287167A1 (en) | 2003-12-24 | 2011-02-23 | Biota Scientific Management Pty. Ltd. | Polycyclic agents for the treatment of respiratory syncytial virus infections |
US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
SI3045206T1 (sl) | 2005-04-28 | 2018-07-31 | Viiv Healthcare Company | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
CA2607151C (en) | 2005-05-10 | 2012-06-19 | Merck & Co., Inc. | Hiv integrase inhibitors |
ATE517899T1 (de) | 2005-10-04 | 2011-08-15 | Angeletti P Ist Richerche Bio | Hiv-integrasehemmer |
BRPI0617842A2 (pt) | 2005-10-27 | 2011-08-09 | Shionogi & Co | composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica |
TWI423972B (zh) | 2006-09-28 | 2014-01-21 | Biota Scient Management | 治療呼吸系融合細胞病毒感染之多環劑 |
JP5269085B2 (ja) * | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
PT2220076E (pt) | 2007-11-15 | 2012-04-26 | Gilead Sciences Inc | Inibidores da replicação do vírus da imunodeficiência humana |
WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
ES2449752T3 (es) * | 2008-07-25 | 2014-03-21 | Viiv Healthcare Company | Proceso para la preparación de un derivado de pirido[1,2-a]pirrolo[1',2':3,4]imidazo[1,2-d]piracin-8-carboxamida |
PT2660239T (pt) * | 2008-07-25 | 2017-02-24 | Shionogi & Co | Compostos químicos como intermediários sintéticos |
WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
WO2010011818A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
EP2320908B9 (en) * | 2008-07-25 | 2014-06-18 | VIIV Healthcare Company | Dolutegravir Prodrugs |
AU2014277831C1 (en) * | 2008-12-11 | 2022-10-06 | Shionogi & Co. Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
US8710249B2 (en) | 2008-12-11 | 2014-04-29 | Shionogi & Co., Ltd. | Maltol ether processes and intermediates |
CN102245182B (zh) * | 2008-12-11 | 2014-07-23 | 盐野义制药株式会社 | 氨基甲酰基吡啶酮hiv整合酶抑制剂和中间体的合成 |
CN106986823A (zh) | 2008-12-11 | 2017-07-28 | 盐野义制药株式会社 | 氨甲酰基吡啶酮hiv整合酶抑制剂的方法和中间体 |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
US8927710B2 (en) | 2009-06-15 | 2015-01-06 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoylpyridone derivative |
WO2011011483A1 (en) * | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
EP2488521B1 (en) | 2009-10-13 | 2013-12-18 | Elanco Animal Health Ireland Limited | Macrocyclic integrase inhibitors |
AU2014202404C1 (en) * | 2010-01-27 | 2022-06-23 | Viiv Healthcare Company | Antiviral therapy |
AU2014202406C1 (en) * | 2010-01-27 | 2019-03-07 | Viiv Healthcare Company | Antiviral therapy |
ES2670811T3 (es) | 2010-01-27 | 2018-06-01 | Viiv Healthcare Company | Terapia antivírica |
TWI508968B (zh) * | 2010-02-08 | 2015-11-21 | Biota Scient Management | 用於治療呼吸道融合性病毒感染的化合物 |
EP2540720B1 (en) * | 2010-02-26 | 2015-04-15 | Japan Tobacco, Inc. | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
TWI582097B (zh) * | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
JP5739517B2 (ja) | 2010-04-02 | 2015-06-24 | ヤンセン・アールアンドデイ・アイルランド | 大環状インテグラーゼ阻害剤 |
WO2011129095A1 (ja) * | 2010-04-12 | 2011-10-20 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
US9073941B2 (en) | 2010-06-28 | 2015-07-07 | Academia Sinica | Compounds and methods for treating tuberculosis infection |
HUE054473T2 (hu) | 2010-08-05 | 2021-09-28 | Shionogi & Co | Eljárás HIV-integráz inhibitor hatású vegyületek elõállítására |
TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
MX2013003139A (es) * | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
US8796303B2 (en) | 2010-11-26 | 2014-08-05 | Biota Scientific Management Pty Ltd. | Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections |
US20140213553A1 (en) * | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
US9206197B2 (en) | 2011-09-14 | 2015-12-08 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
CN103974957A (zh) * | 2011-10-12 | 2014-08-06 | 盐野义制药株式会社 | 具有整合酶抑制活性的多环吡啶酮衍生物 |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
LT3141542T (lt) | 2011-12-28 | 2020-09-25 | Global Blood Therapeutics, Inc. | Pakeistieji benzaldehido junginiai ir jų panaudojimas didinant audinių aprūpinimą deguonimi |
EP2931730B1 (en) * | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as hiv integrase inhibitors |
MY164352A (en) | 2012-12-21 | 2017-12-15 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
MX2015008467A (es) * | 2012-12-27 | 2015-09-23 | Japan Tobacco Inc | Derivado sustituido de espiropirido[1,2-a]pirazina y uso medico del mismo como inhibidor de la integrasa del virus de inmunodeficiencia humana. |
EP2767272A1 (en) | 2013-02-18 | 2014-08-20 | Ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
EP2956123A1 (en) | 2013-02-18 | 2015-12-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of dolutegravir |
US9573965B2 (en) | 2013-02-19 | 2017-02-21 | Aurobindo Pharma Ltd | Process for the preparation of Dolutegravir |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
PE20160078A1 (es) | 2013-03-15 | 2016-03-02 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina |
WO2014145040A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG11201507349TA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
US9951079B2 (en) * | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
WO2015001572A2 (en) * | 2013-07-04 | 2015-01-08 | Hetero Research Foundation | Process for the preparation of intermediate of dolutegravir |
PL3252058T3 (pl) * | 2013-07-12 | 2021-07-19 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
NO2865735T3 (sl) | 2013-07-12 | 2018-07-21 | ||
WO2015009927A1 (en) | 2013-07-17 | 2015-01-22 | Ratiopharm Gmbh | Dolutegravir salts |
WO2015019310A1 (en) | 2013-08-07 | 2015-02-12 | Mylan Laboratories Ltd | Process for the preparation of dolute-gravir and intermediates thereof |
WO2015039348A1 (en) * | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
SG11201602217XA (en) * | 2013-09-27 | 2016-04-28 | Merck Sharp & Dohme | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015089847A1 (en) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2015092752A1 (en) | 2013-12-20 | 2015-06-25 | Mylan Laboratories Ltd. | Novel crystalline form of dolutegravir sodium |
WO2015108945A2 (en) | 2014-01-14 | 2015-07-23 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
EP3096763B1 (en) | 2014-01-21 | 2019-12-25 | Laurus Labs Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
SG10201804139VA (en) | 2014-02-07 | 2018-06-28 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
CN107056813B (zh) * | 2014-03-19 | 2019-07-30 | 杭州普晒医药科技有限公司 | 德罗格韦钠盐的晶型及其制备方法 |
WO2015140569A1 (en) | 2014-03-20 | 2015-09-24 | Cipla Limited | Pharmaceutical composition |
ZA201503540B (en) * | 2014-05-20 | 2016-10-26 | Cipla Ltd | Process for preparing polycyclic carbamoyl pyridone derivatives |
TWI677489B (zh) * | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (sl) | 2014-06-20 | 2018-06-23 | ||
WO2016027879A1 (ja) * | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
US11311545B2 (en) | 2014-10-09 | 2022-04-26 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
WO2016092527A1 (en) * | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
WO2016102078A1 (en) | 2014-12-24 | 2016-06-30 | Ratiopharm Gmbh | Solid state forms of dolutegravir sodium |
EP3045461A1 (en) | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Processes for preparing dolutegravir and analogues thereof |
CN107531614B (zh) | 2015-02-06 | 2020-04-10 | 迈兰实验室有限公司 | 德罗格韦的制备方法 |
CZ201599A3 (cs) | 2015-02-13 | 2016-08-24 | Zentiva, K.S. | Pevné formy solí dolutegraviru a způsob jejich přípravy |
EP3285582B1 (en) * | 2015-03-26 | 2020-11-11 | Merck Sharp & Dohme Corp. | Phosphate-substituted quinolizine derivatives useful as hiv integrase inhibitors |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
CN107531727B (zh) * | 2015-04-02 | 2019-11-29 | 吉利德科学公司 | 多环氨甲酰基吡啶酮化合物及其药物用途 |
DK3428170T3 (da) * | 2015-04-28 | 2021-03-01 | Shionogi & Co | Anti-influenza polycyklisk pyridonderivat og prodrug deraf |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
CZ2015537A3 (cs) | 2015-08-04 | 2017-02-15 | Zentiva, K.S. | Pevné formy amorfního dolutegraviru |
ES2969437T3 (es) | 2015-08-19 | 2024-05-20 | Laurus Labs Ltd | Polimorfos novedosos de dolutegravir y de sales del mismo |
TW202220660A (zh) | 2015-11-09 | 2022-06-01 | 美商基利科學股份有限公司 | 用於治療人類免疫缺乏病毒之治療組合物 |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
MX2018006832A (es) | 2015-12-04 | 2018-11-09 | Global Blood Therapeutics Inc | Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido. |
EP3389380B1 (en) | 2015-12-15 | 2021-07-21 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
WO2017109649A1 (en) | 2015-12-21 | 2017-06-29 | Lupin Limited | Process for the preparation of hiv integrase inhibitors |
TWI825524B (zh) | 2016-05-12 | 2023-12-11 | 美商全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
WO2017208105A1 (en) | 2016-05-30 | 2017-12-07 | Lupin Limited | Novel crystalline form of dolutegravir sodium |
WO2017223280A2 (en) * | 2016-06-23 | 2017-12-28 | Viiv Healthcare Company | Compositions and methods for the delivery of therapeutics |
US11045423B2 (en) | 2016-08-08 | 2021-06-29 | Hetero Labs Limited | Anti-retroviral compositions |
ES2952878T3 (es) | 2016-08-08 | 2023-11-06 | Hetero Labs Ltd | Una composición antirretroviral multiclase |
CA3033667A1 (en) * | 2016-08-12 | 2018-02-15 | Nanjing Gator Meditech Company, Ltd. | Protein kinase regulators |
WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
WO2018057408A1 (en) * | 2016-09-21 | 2018-03-29 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of integrase inhibitors |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
WO2018109786A1 (en) | 2016-12-16 | 2018-06-21 | Cipla Limited | Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives |
WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
MX2019009810A (es) | 2017-02-16 | 2019-12-02 | Sandoz Ag | Formas cristalinas de cabotegravir de sodio. |
EP3363802B1 (en) * | 2017-02-16 | 2019-11-20 | Sandoz AG | Crystalline form of cabotegravir sodium |
US20200138845A1 (en) * | 2017-07-18 | 2020-05-07 | Viiv Healthcare Company | Combination Drug Therapy |
US11564921B2 (en) | 2017-07-21 | 2023-01-31 | Viiv Healthcare Company | Regimens for treating HIV infections and AIDS |
US20210040116A1 (en) | 2017-09-07 | 2021-02-11 | Cipla Limited | New Polymorphs of Dolutegravir Sodium |
CN111386276B (zh) | 2017-10-06 | 2023-06-23 | 盐野义制药株式会社 | 制备取代的多环吡啶酮衍生物的立体选择性方法 |
CA3126348A1 (en) | 2018-01-12 | 2020-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
CN110526930B (zh) | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
MX2020012176A (es) | 2018-05-31 | 2021-01-29 | Shionogi & Co | Derivado policiclico de carbamoilpiridona. |
PE20201414A1 (es) * | 2018-05-31 | 2020-12-07 | Shionogi & Co | Derivado policiclico de piridona |
TW202323254A (zh) * | 2018-05-31 | 2023-06-16 | 日商鹽野義製藥股份有限公司 | 多環性吡啶并三𠯤衍生物 |
US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
AU2019368247A1 (en) | 2018-10-22 | 2021-06-03 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
MX2021011394A (es) | 2019-03-22 | 2021-10-13 | Gilead Sciences Inc | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. |
RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
WO2021173522A1 (en) | 2020-02-24 | 2021-09-02 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
JP2023539344A (ja) | 2020-09-01 | 2023-09-13 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルおよびレボノルゲストレルの組合せ |
WO2022079739A1 (en) | 2020-10-14 | 2022-04-21 | Cipla Limited | Fixed dose compositions of cabotegravir and rilpivirine |
EP4255472A2 (en) | 2020-12-07 | 2023-10-11 | VIIV Healthcare Company | Combination therapy |
LT4196479T (lt) | 2021-01-19 | 2023-12-11 | Gilead Sciences, Inc. | Pakeistieji piridotriazino junginiai ir jų panaudojimo būdai |
CN117715908A (zh) | 2021-06-03 | 2024-03-15 | 江苏恒瑞医药股份有限公司 | 具有整合酶抑制活性的吡啶酮化合物及其药用用途 |
CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
WO2023102374A1 (en) | 2021-12-03 | 2023-06-08 | Viiv Healthcase Company | Process of synthesizing (r)-3-aminobutan-1-ol |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3959316A (en) * | 1972-03-13 | 1976-05-25 | Snam Progetti S.P.A. | Procedure for propylene oxide synthesis |
JPH0296506A (ja) * | 1988-09-30 | 1990-04-09 | Daicel Chem Ind Ltd | 除草剤組成物 |
JP2533796B2 (ja) * | 1988-10-18 | 1996-09-11 | ダイセル化学工業株式会社 | 5−アルコキシピリジン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
JP2551472B2 (ja) | 1988-10-18 | 1996-11-06 | ダイセル化学工業株式会社 | 5−アルコキシ−γ−ピロン−3−カルボキサミド誘導体とその製造方法及び植物成長抑制剤 |
RU2220960C2 (ru) | 1997-12-22 | 2004-01-10 | Фармация Энд Апджон Компани | 4-гидрокси-3-хинолинкарбоксамиды и гидразиды, фармацевтическая композиция и способ лечения на их основе |
EP1297834A4 (en) † | 2000-06-14 | 2007-05-09 | Shionogi & Co | ENZYME INHIBITOR HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS |
US6580562B2 (en) | 2000-07-24 | 2003-06-17 | Yazaki Corporation | On-vehicle display unit |
US6384263B1 (en) | 2000-08-04 | 2002-05-07 | E. I. Du Pont De Nemours And Company | Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane |
JP4287649B2 (ja) | 2000-10-12 | 2009-07-01 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
JP2003032772A (ja) | 2001-07-12 | 2003-01-31 | Foster Electric Co Ltd | 耳掛け式イヤホン |
EP2266958B1 (en) | 2001-08-10 | 2017-03-15 | Shionogi & Co., Ltd. | Antiviral agent |
ME00427B (me) | 2001-10-26 | 2011-10-10 | Msd Italia Srl | N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze |
ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
JP3908248B2 (ja) | 2002-08-13 | 2007-04-25 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するヘテロ環化合物 |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
PL377354A1 (pl) | 2002-12-27 | 2006-01-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4H-pirydo[1,2-a]pirymidyny i związki pokrewne użyteczne jako inhibitory integrazy HIV |
US6960680B2 (en) | 2003-01-08 | 2005-11-01 | Rhodia Chirex, Inc. | Manufacture of water-soluble β-hydroxynitriles |
JP2004244320A (ja) | 2003-02-10 | 2004-09-02 | Shionogi & Co Ltd | 含窒素複素環抗ウイルス剤 |
EP1622615A4 (en) | 2003-05-13 | 2009-02-18 | Smithkline Beecham Corp | INHIBITORS OF THE INTEGRASE OF NAPHTHYRIDINE |
WO2005015927A1 (en) * | 2003-08-12 | 2005-02-17 | Rachel Beijer | Scheduled message service |
TW200510425A (en) * | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
JP4530642B2 (ja) | 2003-10-31 | 2010-08-25 | オリンパス株式会社 | 内視鏡装置 |
RU2006128848A (ru) | 2004-02-11 | 2008-03-20 | СмитКлайн Бичем Корпорейшн (US) | Ингибиторы вич-интегразы |
CA2557785A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co. Inc. | Hiv integrase inhibitors |
JP2007528379A (ja) | 2004-03-09 | 2007-10-11 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Hivインテグラーゼ阻害薬 |
WO2005110414A2 (en) | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
JP5116660B2 (ja) | 2005-03-31 | 2013-01-09 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Hivインテグラーゼ阻害剤 |
SI3045206T1 (sl) * | 2005-04-28 | 2018-07-31 | Viiv Healthcare Company | Policiklični karbamoilpiridonski derivat z inhibitorno aktivnostjo za HIV integrazo |
JP2005312076A (ja) | 2005-05-26 | 2005-11-04 | Olympus Corp | 電子撮像装置 |
EP1910363A4 (en) | 2005-08-04 | 2010-05-26 | Glaxosmithkline Llc | INHIBITORS OF HIV INTEGRASE |
BRPI0617842A2 (pt) | 2005-10-27 | 2011-08-09 | Shionogi & Co | composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica |
-
2006
- 2006-04-28 SI SI200632268T patent/SI3045206T1/sl unknown
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/en not_active Withdrawn
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/en active Active
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/en active Active
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/en not_active Withdrawn
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/en active Active
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active IP Right Review Request
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/en active Active
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active IP Right Grant
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/en active Application Filing
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active IP Right Grant
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 CA CA2606282A patent/CA2606282C/en active Active
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/en active Active
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active IP Right Review Request
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/en active Active
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/en active Active
-
2007
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
-
2008
- 2008-01-24 HK HK08100942.1A patent/HK1107227A1/xx unknown
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
-
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
-
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
- 2012-12-18 HK HK12113039.2A patent/HK1172282A1/xx unknown
-
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
-
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/xx unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-25 CY CY2014024C patent/CY2014024I1/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
-
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
-
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
-
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I1/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
-
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/zh unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/zh unknown
-
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
-
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
-
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-06-08 NL NL301109C patent/NL301109I1/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
-
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
-
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100023I1 (hu) | HIV integráz inhibitor hatású policiklusos karbamoil-piridon származékok | |
IL190879A0 (en) | Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase | |
EP1790638A4 (en) | CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY | |
PL1948666T3 (pl) | Inhibitory integrazy HIV | |
ZA200803423B (en) | Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase | |
EP1881825A4 (en) | INHIBITORS OF HIV INTEGRASE | |
EP1910363A4 (en) | INHIBITORS OF HIV INTEGRASE | |
EP1910356A4 (en) | HIV integrase | |
IL189939A0 (en) | Inhibitors of the hiv integrase enzyme | |
EP1909578A4 (en) | INHIBITORS OF HIV INTEGRASE | |
EP1910355A4 (en) | HIV integrase |